Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

796
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
796
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

349
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
349
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

738
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
738
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

680
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
680
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

547
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
547
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

513
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
513

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The mechanisms of anti-inflammatory action of enisamium iodide].

Terapevticheskii arkhiv·2023
Same author

[Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020].

Terapevticheskii arkhiv·2022
Same author

[Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia].

Terapevticheskii arkhiv·2020
Same author

Nephrolithiasis against type 2 diabetes mellitus: on the effect of hypoglycemic therapy on lithogenesis.

Terapevticheskii arkhiv·2019
Same author

[Effects of oral hypoglycemic drugs on lithogenic properties of urine in nephrolithiasis patients with concurrent type 2 diabetes].

Urologiia (Moscow, Russia : 1999)·2018
Same author

[INFLUENCE OF PROGESTERONE DERIVATIVES ON THE VIABILITY AND EXPRESSION OF ESTROGEN RECEPTOR-ALPHA MRNA IN HELA CELLS.]

Eksperimental'naia i klinicheskaia farmakologiia·2018

Related Experiment Video

Updated: Dec 17, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.6K

[NSAID enteropathy].

E N Kareva1,2

  • 1Sechenov First Moscow State Medical University (Sechenov University).

Terapevticheskii Arkhiv
|June 30, 2020
PubMed
Summary
This summary is machine-generated.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can damage the small intestine, leading to NSAID enteropathy. Probiotics may offer a therapeutic strategy to prevent and treat this common side effect by modulating intestinal flora.

Keywords:
NSAIDsenteropathymicrobiotapathogenesisprobiotics

More Related Videos

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.2K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K

Related Experiment Videos

Last Updated: Dec 17, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.6K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

20.2K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.4K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Microbiology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used globally.
  • NSAID use is associated with significant gastrointestinal side effects, including NSAID gastropathy and NSAID enteropathy.
  • NSAID enteropathy affects 50-70% of long-term users, potentially causing severe complications.

Purpose of the Study:

  • To explore the pathogenesis of NSAID enteropathy.
  • To identify potential therapeutic strategies for preventing NSAID-induced small intestinal damage.
  • To investigate the role of gut microbiota in NSAID enteropathy.

Main Methods:

  • Review of existing literature on NSAID enteropathy mechanisms.
  • Analysis of the hypothesis implicating gut microflora in NSAID enteropathy development.
  • Exploration of probiotic modulation of intestinal flora as a preventive measure.

Main Results:

  • The exact pathogenesis of NSAID enteropathy is not fully understood.
  • A leading hypothesis suggests the involvement of specific gut microorganisms in its development.
  • Currently, no drugs are proven effective in preventing NSAID enteropathy.

Conclusions:

  • Modulating the intestinal flora with probiotics presents a promising therapeutic strategy.
  • Probiotics may be a foundational treatment for preventing and managing NSAID enteropathy.
  • Targeting the gut microbiota could mitigate the long-term intestinal damage caused by NSAIDs.